Supercharged immune cells take on deadly brain tumors
NCT ID NCT07244666
First seen Jan 11, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-phase trial tests a new type of immune cell therapy (CAR-T) for people with recurrent glioblastoma, an aggressive brain cancer. The therapy is designed to target a specific protein (EGFRvIII) found on cancer cells and includes a metabolic boost to help the cells work better. The study will enroll 36 adults to check safety and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.